Efficiently generating ADME data with rapid turnaround time in a high-throughput drug discovery and development laboratory requires automated LC–MS method optimization without compromising data integrity. DiscoveryQuant™ 3.0 software simplifies and reduces LC–MS method development cycle time with fast, robust and reliable processes that optimize MRM methods for small or large molecules. It utilizes a global database, enabling shared access across multiple locations within or between companies. The new chromatune feature in DiscoveryQuant 3.0 automates on-column MRM optimization enabling sample analysis during the earliest phase of MRM optimization. This new capability helps identify interferences and reduce false positives in complex matrices before real-sample analysis, which increases laboratory productivity. DiscoveryQuant 3.0 software is supported on all AB SCIEX MS platforms including the TripleTOF® high-resolution accurate mass system and seamlessly communicates with MultiQuant™ 3.0 to further leverage data processing capabilities. DiscoveryQuant software ensures success for everyone involved in drug discovery and development.
What will you learn?
• How to reduce tedious LC–MS method development time for NCEs and NBEs
• How to automate on column optimization
• How to rapidly build and submit batches and process results for study samples
• How to share database information across multiple sites
• Scientists in pharmaceutical and biopharmaceutical laboratories
• HT-ADME screening scientists
• Bioanalytical laboratory managers
Ian Moore is an applications scientist in the product applications laboratory at AB SCIEX in Toronto, Canada. Ian has years of experience in high-throughput drug discovery and ADME screening in both a pharmaceutical and CRO environment. He joined AB SCIEX in 2012 where he has focused on the development and application of DiscoveryQuant™ software. Ian is a graduate of the University of Toronto and holds a PhD in organic chemistry.
Mark C Woodward
Mark Woodward is an Investigator supporting Enteroendocrine DMPK within the Metabolic Pathways and Cardiovascular Therapy Area at GlaxoSmithKline in Research Triangle Park, NC, USA. Mark has been supporting DMPK activities at GSK for over 17 years and has extensive experience developing and optimizing high-throughput LC–MS workflows using triple quadrupole and Q-TOF mass spectrometers. Mark earned his BS in Biology with a minor in chemistry from Western Carolina University (NC, USA).